| Tobacco Regulatory Science Program |
Research Initiative |
FDA |
NCI, NHLBI, NIDA, NIEHS, OD/DPCPSI/ODP |
Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources. (language updated by ODP TRSP) The Tobacco Regulatory Science Program (TRSP) is an interagency partnership between the National Institutes of Health and the Food and Drug Administration (FDA) Center for Tobacco Products to foster tobacco regulatory research. With funds from the FDA, NIH can provide new funding opportunities in tobacco regulatory science that complement existing NIH tobacco research activities. TRSP awards R01, K01, K99/R00, and U54s. Activities include research awards, annual meetings, manufacture and distribution of nicotine research cigarettes, online resources, and data sharing. |
| Tobacco Regulatory Science Program (TRSP) |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCI |
With the passage of the 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), the FDA acquired the authority to regulate the manufacture, marketing, and distribution of tobacco products in order to protect public health. To better inform FDA’s regulatory authorities, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research, capitalizing on NIH’s infrastructure to support tobacco-related research and funding from FDA. |
| Tobacco Use Supplement to the Current Population Survey |
Health Survey |
CDC, FDA |
NCI, NIMHD |
The Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is an NCI-sponsored survey of tobacco use that has been administered as part of the U.S. Census Bureau's Current Population Survey approximately every 3-4 years since 1992-93. |
| Toxic Exposure Research Work Group |
Committee, Work group, Advisory group, or Task Force |
CDC |
NIEHS |
The Toxic Exposure Research Working Group was established under Section 501 of the Honoring our PACT Act in 2023. Under 38 USC § 501, a multi-agency federal working group called the Toxic Exposure Research Working Group will identify collaborative toxic exposure research studies and develop a 5-year strategic plan. |
| Toxicology in the 21st Century (Tox 21) |
Resource Development |
FDA |
NCATS, NIEHS |
The Toxicology in the 21st Century (Tox21) program is a federal collaboration among NIH's National Center for Advancing Translational Science (NCATS) and the National Toxicology Program (now called Division of Translational Toxicology, NIEHS; the Environmental Protection Agency; and the Food and Drug Administration. Tox21 researchers aim to develop better toxicity assessment methods to quickly and efficiently test whether certain chemical compounds have the potential to disrupt processes in the human body that may lead to negative health effects. |
| Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA |
NIAID |
The workgroup holds biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the Centers for Disease Control and Prevention (CDC) manual “Biosafety in Microbiological and Biomedical Laboratories.” |
| Toxins Assessment Working Group |
Committee, Work group, Advisory group, or Task Force |
ASPR, CDC, FDA |
NIAID |
Biological (not engineered) toxins with specific effects on the nervous system, focusing on neurotoxins, applications in medical research and historical consideration as bioweapons |
| Training Advisory Committee |
Committee, Work group, Advisory group, or Task Force |
AHRQ |
CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORIP, OD/OER |
The Training Advisory Committee (TAC) advises on programmatic, review, and management issues related to extramural research training, research education, career development programs and the Loan Repayment Programs (LRP), and evaluation of these programs. TAC provides an NIH-wide forum to identify and discuss issues related to these programs and recommend solutions. |
| Training Institute for Dissemination and Implementation in Genomics and Precision Public Health (TIDIR-GPPH) |
Training Initiative |
CDC |
NCI, NHGRI, NHLBI |
This training course is intended to provide investigators at any career stage with a thorough grounding in conducting dissemination and implementation (D&I) research with a focus on genomics and precision public health. TIDIR-GPPH will be a hybrid course including training through open access online modules with assigned reading material, office hours, and culminating with a 2-day in-person event on September 5-6, 2024. (Please note: The online material is not cancer-specific, and applicable to all focus areas). |
| Trans-Agency (Medical) Imaging Phantom (TAIP) Workgroup |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCI, NIBIB |
A common set of scientifically validated medical phantoms that have long term curation, convenient dissemination, associated measurement protocols and analysis software will be of great benefit to the FDA, NIH, NIST and to the scientific community they serve. This working group is created to enhance collaboration between FDA, NIST, and NIH to cooperate, where possible, on the development, validation, and dissemination of these medical calibration objects and to establish and maintain a library of these medical phantoms for use by the larger medical community. |